Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANAPTYSBIO, INC Director's Dealing 2017

Jan 26, 2017

32596_dirs_2017-01-25_60433f40-a405-42da-bc33-216291e1c87f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ANAPTYSBIO INC (ANAB)
CIK: 0001370053
Period of Report: 2017-01-25

Reporting Person: Suria Hamza (Director, President, CEO)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series C Preferred Stock $0.00 Common Stock (2197) Direct
Series C-1 Preferred Stock $0.00 Common Stock (781) Direct
Series D Preferred Stock $0.00 Common Stock (2020) Direct
Employee Stock Option (right to buy) $2.59 2018-12-08 Common Stock (22428) Direct
Employee Stock Option (right to buy) $2.24 2020-02-09 Common Stock (1428) Direct
Employee Stock Option (right to buy) $1.61 2021-02-23 Common Stock (6208) Direct
Employee Stock Option (right to buy) $1.12 2021-12-08 Common Stock (140948) Direct
Employee Stock Option (right to buy) $1.12 2022-01-31 Common Stock (73291) Direct
Employee Stock Option (right to buy) $1.12 2022-01-31 Common Stock (97721) Direct
Employee Stock Option (right to buy) $0.91 2022-12-16 Common Stock (19425) Direct
Employee Stock Option (right to buy) $0.70 2024-09-15 Common Stock (51840) Direct
Employee Stock Option (right to buy) $6.93 2025-08-13 Common Stock (265928) Direct

Footnotes

F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.

F2: The stock option is fully vested and immediately exercisable.

F3: The stock option becomes 100% vested upon the Issuer's initial public offering, subject to the Reporting Person's employment on such date.

F4: The stock option vested and became exercisable as to 25% of the shares subject to the option on December 17, 2013, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F5: The stock option vested and became exercisable as to 25% of the shares subject to the option on September 16, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F6: The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.